VIOLIN Logo
VO Banner
Search: for Help
Vaxvec Home
Introduction
Statistics
News and Updates
Vaxvec Vectors
Vaxvec Vaccines
Vaxvec Antigens
VaxvecAg BLAST
Selected Vectors
B. abortus RB51 vector
RSV vaccine vector
SL3261 vaccine vector
VSV vaccine vector
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

A2-CPA-CPB(-CTE)-recombinant L. tarentolae
Vaccine Information
  • Vaccine Ontology ID: VO_0004628
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Recombinant L. tarentolae expressing the L. donovani A2 antigen along with cysteine proteinases (CPA and CPB without its unusual C-terminal extension (CPB(-CTE))) as a tri-fusion gene (Saljoughian et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Saljoughian et al., 2013: Saljoughian N, Taheri T, Zahedifard F, Taslimi Y, Doustdari F, Bolhassani A, Doroud D, Azizi H, Heidari K, Vasei M, Namvar Asl N, Papadopoulou B, Rafati S. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS neglected tropical diseases. 2013; 7(4); e2174. [PubMed: 23638195].
BDES-PfCSP (baculovirus dual expression system)
Vaccine Information
  • Vaccine Ontology ID: VO_0004801
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Vector:
  • Preparation: (Iyori et al., 2013)
  • Immunization Route: Intramuscular injection (i.m.)
References
Iyori et al., 2013: Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, Kawasaki M, Kwak K, Mizukoshi M, Goto Y, Matsuoka H, Matsumoto M, Yoshida S. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PloS one. 2013; 8(8); e70819. [PubMed: 23951015].
ChAd63 -PvTRAP
Vaccine Information
  • Vaccine Ontology ID: VO_0004797
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Vector:
  • Preparation: (Bauza et al., 2014) the recombinant ChAd63 vectors expressing P. vivax TRAP (PvTRAP).
  • Immunization Route: Intramuscular injection (i.m.)
References
Bauza et al., 2014: Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infection and immunity. 2014; 82(3); 1277-1286. [PubMed: 24379295].
L. T -PpSP15
Vaccine Information
  • Vaccine Ontology ID: VO_0004627
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: CPA/CPB(Zahedifard et al., 2014)
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: A Leishmania major recombinant vector vaccine that uses a Salmonella vector and CPA/CPB as antigen (Zahedifard et al., 2014).
References
Zahedifard et al., 2014: Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N, Torkashvand F, Meneses C, Papadopoulou B, Kamhawi S, Valenzuela JG, Rafati S. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen. PLoS neglected tropical diseases. 2014; 8(3); e2751. [PubMed: 24675711].
MVA-PvTRAP
Vaccine Information
  • Vaccine Ontology ID: VO_0004796
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Vector:
  • Preparation: (Bauza et al., 2014) the recombinant MVA vectors expressing P. vivax TRAP (PvTRAP) .
  • Immunization Route: Intramuscular injection (i.m.)
References
Bauza et al., 2014: Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infection and immunity. 2014; 82(3); 1277-1286. [PubMed: 24379295].
NILV-Py CSP
Vaccine Information
  • Vaccine Ontology ID: VO_0004798
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Vector:
  • Preparation: (Coutant et al., 2012) nonintegrative lentiviral vectors (NILV) encoding Plasmodium yoelii Circumsporozoite Protein (Py CSP), and challenged with sporozoites one month later. 50% (37.5-62.5) of the animals were fully protected. Moreover, protection was long-lasting with 42.8% sterile protection six months after the last immunization.
  • Immunization Route: Intramuscular injection (i.m.)
References
Coutant et al., 2012: Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS, Charneau P. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PloS one. 2012; 7(11); e48644. [PubMed: 23133649].
NYVAC-CSP (malaria)
Vaccine Information
  • Vaccine Ontology ID: VO_0004800
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Host Species as Laboratory Animal Model: mouse
  • Vector:
  • Preparation: (Lanar et al., 1996) NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%).
  • Immunization Route: Intramuscular injection (i.m.)
References
Lanar et al., 1996: Lanar DE, Tine JA, de Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infection and immunity. 1996; 64(5); 1666-1671. [PubMed: 8613376].
rAdV-SjTPI.opt
Vaccine Information
  • Vaccine Ontology ID: VO_0004782
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Replication-defective adenoviral vector-based vaccine with optimized SjTPI (rAdV-SjTPI.opt) (Dai et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
RB51--MIC3/GRA2/GRA6/MIC1/SRS2
Vaccine Information
  • Vaccine Ontology ID: VO_0004649
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • MIC1 gene engineering:
    • Type: Recombinant vector construction
    • Description: Neospora caninum protective antigens MIC1, MIC3, GRA2, GRA6 and RS2 were expressed in strain RB51 (Ramamoorthy et al., 2007).
    • Detailed Gene Information: Click Here.
  • SRS2 gene engineering:
    • Type: Recombinant vector construction
    • Description: Neospora caninum protective antigens MIC1, MIC3, GRA2, GRA6 and RS2 were expressed in strain RB51 (Ramamoorthy et al., 2007).
    • Detailed Gene Information: Click Here.
  • GRA6 gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A recombinant strain RB51 expressing N. caninum antigen. Neospora caninum protective antigens MIC1, MIC3, GRA2, GRA6 and SRS2 were expressed in strain RB51 (Ramamoorthy et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
Ramamoorthy et al., 2007: Ramamoorthy S, Sanakkayala N, Vemulapalli R, Jain N, Lindsay DS, Schurig GS, Boyle SM, Sriranganathan N. Prevention of vertical transmission of Neospora caninum in C57BL/6 mice vaccinated with Brucella abortus strain RB51 expressing N. caninum protective antigens. International journal for parasitology. 2007; 37(13); 1531-1538. [PubMed: 17575983].
RB51-SRS2
Vaccine Information
  • Vaccine Ontology ID: VO_0004648
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • SRS2 gene engineering:
    • Type: Recombinant vector construction
    • Description: Recombinant RB51 strains each expressing SRS2 (RB51/SRS2) or GRA7 (RB51/GRA7) antigens of N. caninum (Alaeddine et al., 2005).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: RB51 strains expressing SRS2 (RB51/SRS2) or GRA7 (RB51/GRA7) antigens of N. caninum (Vemulapalli et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
Alaeddine et al., 2005: Alaeddine F, Keller N, Leepin A, Hemphill A. Reduced infection and protection from clinical signs of cerebral neosporosis in C57BL/6 mice vaccinated with recombinant microneme antigen NcMIC1. The Journal of parasitology. 2005; 91(3); 657-665. [PubMed: 16108562].
Vemulapalli et al., 2007: Vemulapalli R, Sanakkayala N, Gulani J, Schurig GG, Boyle SM, Lindsay DS, Sriranganathan N. Reduced cerebral infection of Neospora caninum in BALB/c mice vaccinated with recombinant Brucella abortus RB51 strains expressing N. caninum SRS2 and GRA7 proteins. Veterinary parasitology. 2007; 148(3-4); 219-230. [PubMed: 17651896].
rBCGMSP1-15
Vaccine Information
  • Vaccine Ontology ID: VO_0004791
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Antigen: MSP1-15 as a fusion protein with the α antigen of Mycobacterium kansasii (α-k), which is secreted from the rBCG vaccine vector (Matsumoto et al., 1998).
  • MSP1 from P. yoelii str. 17XNL gene engineering:
    • Type: Recombinant vector construction
    • Description: A 2.4-kbp fragment containing an α-k–MSP1-15 hybrid gene was subcloned into pSO246. The final construct (designated pSOMSP1-15) was transformed into BCG Tokyo by electroporation (Matsumoto et al., 1998).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Immunization Route: Intravenous injection (i.v.)
References
Matsumoto et al., 1998: Matsumoto S, Yukitake H, Kanbara H, Yamada T. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. The Journal of experimental medicine. 1998; 188(5); 845-854. [PubMed: 9730886].
rBCGpMV361-TgCyP
Vaccine Information
  • Vaccine Ontology ID: VO_0004656
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • CyP gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG (Yu et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Yu et al., 2013: Yu Q, Huang X, Gong P, Zhang Q, Li J, Zhang G, Yang J, Li H, Wang N, Zhang X. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Vaccine. 2013; ; . [PubMed: 24176493].
S. gordonii -M6-Sj-F1
Vaccine Information
  • Vaccine Ontology ID: VO_0004668
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
SAd-ME.TRAP
Vaccine Information
  • Vaccine Ontology ID: VO_0004799
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Vector:
  • Preparation: (Reyes-Sandoval et al., 2008) AdC7 and AdC9 elicited strong immunogenicity ( approximately 20% of CD8(+) T cells in spleen), equivalent to or outperforming AdH5 and inducing sterile protection in 92% (C9), 83% (H5 and C7) and 67% (C6) of the mice, providing the first evidence of single-dose protection to Plasmodium berghei.
  • Immunization Route: Intramuscular injection (i.m.)
References
Reyes-Sandoval et al., 2008: Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European journal of immunology. 2008; 38(3); 732-741. [PubMed: 18266272].
SL3261 expressing T. spiralis Ag30
Vaccine Information
  • Vaccine Ontology ID: VO_0004605
  • Type: Recombinant vector vaccine
  • Status: Research
  • Antigen: The antigen expressed on S. enterica is the "210-239 amino acid epitope, (designated as Ag30) derived from the 43 kDa glycoprotein of T. spiralis muscle larvae" (Pompa-Mera et al., 2011).
  • Vector:
  • Preparation: (Pompa-Mera et al., 2011)
  • Immunization Route: intranasal immunization
  • Description: This vaccine was shown to elicit protective immunity against T. spiralis challenge, in the form of the induction of antigen-specific IgG1 and IL-5 production (Pompa-Mera et al., 2011).
References
Pompa-Mera et al., 2011: Pompa-Mera EN, Yépez-Mulia L, Ocaña-Mondragón A, García-Zepeda EA, Ortega-Pierres G, González-Bonilla CR. Trichinella spiralis: intranasal immunization with attenuated Salmonella enterica carrying a gp43 antigen-derived 30mer epitope elicits protection in BALB/c mice. Experimental parasitology. 2011; 129(4); 393-401. [PubMed: 21907709].
SL3261-L. donovani
Vaccine Information
  • Vaccine Ontology ID: VO_0004672
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Host Species as Laboratory Animal Model: mouse
  • KMP-11 gene engineering:
    • Type: Recombinant vector construction
    • Description: The sequence encoding cholera toxin B subunit signal peptide was followed by SpeI/BglII sites for in frame directional cloning of ORF of interest fused with downstream sequences coding for a hemagglutinin epitope (HA)-tag and the transporter domain of AIDA (Schroeder et al., 2011)
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Five chosen antigens were differentially expressed on the surface or in the cytosol of Salmonella typhimurium SL3261. A two-step procedure was developed to select optimal Salmonella vaccine strains for each antigen, based on bacterial fitness and antigen expression levels (Schroeder et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Schroeder et al., 2011: Schroeder J, Brown N, Kaye P, Aebischer T. Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice. PLoS neglected tropical diseases. 2011; 5(12); e1406. [PubMed: 22216363].
SL3261-L. major
Vaccine Information
  • Vaccine Ontology ID: VO_0004671
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Host Species as Laboratory Animal Model: mouse
  • KMP-11 gene engineering:
    • Type: Recombinant protein preparation
    • Description: Antigens were differentially expressed on the surface or in the cytosol of Salmonella typhimurium SL3261 (Schroeder et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Salmonella expressing the novel Leishmania antigens LinJ08.1190 and LinJ23.0410 (Schroeder et al., 2011)
  • Immunization Route: Intramuscular injection (i.m.)
References
Schroeder et al., 2011: Schroeder J, Brown N, Kaye P, Aebischer T. Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice. PLoS neglected tropical diseases. 2011; 5(12); e1406. [PubMed: 22216363].
T. gondii recombinant vaccine vector rBCGpMV361-TgCyP
Vaccine Information
  • Vaccine Ontology ID: VO_0004602
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Antigen: TgCyP(Yu et al., 2013)
  • Vector:
    • Vactor Name:
    • VO ID: VO_0001023
    • Description: Mycobacterium bovis is used as a live vaccine vector. This stdy has shown that a "BCG vector expressing a target antigen, TgCyP, represent an alternative system for the production of effective vaccines to prevent toxoplasmosis" (Yu et al., 2013).
  • Immunization Route: Intravenous injection (i.v.)
References
Yu et al., 2013: Yu Q, Huang X, Gong P, Zhang Q, Li J, Zhang G, Yang J, Li H, Wang N, Zhang X. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Vaccine. 2013; ; . [PubMed: 24176493].